For: | Dang H, Sun J, Wang G, Renner G, Layfield L, Hilli J. Management of pembrolizumab-induced steroid refractory mucositis with infliximab: A case report. World J Clin Cases 2020; 8(18): 4100-4108 [PMID: 33024767 DOI: 10.12998/wjcc.v8.i18.4100] |
---|---|
URL: | https://www.wjgnet.com/2307-8960/full/v8/i18/4100.htm |
Number | Citing Articles |
1 |
Barbara Ma, Niroshana Anandasabapathy. Immune Checkpoint Blockade and Skin Toxicity Pathogenesis. Journal of Investigative Dermatology 2022; 142(3): 951 doi: 10.1016/j.jid.2021.06.040
|
2 |
Naoki Kawakami, Hiroaki Saito, Susumu Takahashi, Shinpei Kajie, Rina Kato, Kazuhiro Shimaya, Yoko Wakai, Kazuhito Saito, Mai Sakashita. Airway disorders associated with immune checkpoint inhibitor therapy: Two case reports and a systematic review. Seminars in Oncology 2022; 49(6): 439 doi: 10.1053/j.seminoncol.2023.01.003
|
3 |
Malek Shatila, Hao Chi Zhang, Anusha Shirwaikar Thomas, Antonio Pizuorno Machado, Sidra Naz, Nitish Mittal, Christine Catinis, Krishnavathana Varatharajalu, Carolina Colli Cruz, Eric Lu, Deanna Wu, Julie R Brahmer, Franck Carbonnel, Stephen B Hanauer, Bret Lashner, Bryan Schneider, John A Thompson, Michel Obeid, David P Farris, Yinghong Wang. Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events. Journal for ImmunoTherapy of Cancer 2024; 12(11): e009742 doi: 10.1136/jitc-2024-009742
|
4 |
Siyuan Hao, Yixin Jin, Yue Yu, Jiantao Wang, Jing Zou, Yan Wang. Identification of potential molecular mechanisms and candidate drugs for radiotherapy- and chemotherapy-induced mucositis. Supportive Care in Cancer 2023; 31(4) doi: 10.1007/s00520-023-07686-7
|
5 |
|